SOLICITATION NOTICE
A -- Bangkok Tenefovir Drug Study
- Notice Date
- 3/30/2007
- Notice Type
- Solicitation Notice
- NAICS
- 541710
— Research and Development in the Physical, Engineering, and Life Sciences
- Contracting Office
- Department of Health and Human Services, Center for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, GA, 30341-4146, UNITED STATES
- ZIP Code
- 00000
- Solicitation Number
- 2007-N-09240
- Response Due
- 4/14/2007
- Archive Date
- 4/29/2007
- Description
- The Centers for Disease Control and Prevention (CDC) intends to award a contract to the Bangkok Tenofivir Study Group on a cost only (no fee) basis. The Bangkok Tenofovir Study (BTS) is a Phase II/III randomized, double-blind, placebo-controlled study of the safety and efficacy of tenofovir, administered once daily to HIV-1 uninfected Intravenous Drug Users in Bangkok Thailand. The study is designed to determine if daily tenofovir will prevent HIV-1 infection among IDUs and if tenofovir is safe to use among HIV-uninfected IDUs. The purpose of this contract is to continue the study initiated under an existing contract with the Bangkok Tenofovir Study Group (contract 200-2004-09965) to allow an increase in study cohort size, and an extension of participant follow up. BTS is designed to determine if daily tenofovir will prevent HIV-1 infection among IDUs and if tenofovir is safe to use among HIV-uninfected IDUs. This is a Phase II/III randomized, double-blind placebo controlled study of the safety and efficacy of tenofovir, administered once daily to HIV-1 uninfected IDUs. HIV-uninfected IDUs (N=2,000) will be randomized to receive either tenofovir 300 mg daily (N=1000) or placebo (N=1000). Participants will be involved in the study until the last enrollee completes 12 months on study, with an expected contract period from June 2007 through December 2008. For continuation and consistency of this research it is imperative to utilize BTSG for this follow-on contract. BTSG?s ability to continue their work will prevent this trial from ending prematurely or will prevent CDC from having to start this research project from the beginning. The North American Industry Classification Code is 541710. Note 22.
- Place of Performance
- Address: Bangkok
- Country: THAILAND
- Country: THAILAND
- Record
- SN01262877-W 20070401/070330220414 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |